Status:
COMPLETED
Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers
Lead Sponsor:
Marinomed Biotech AG
Conditions:
Respiratory Viral Infection
Common Cold
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This is a prospective, randomized placebo-controlled double blinded clinical trial in frontline healthcare workers managing COVID-19 patients. Participants will be weekly tested for SARS-CoV-2 and a p...
Detailed Description
This is a prospective, randomized placebo-controlled double blinded clinical trial in frontline healthcare workers managing COVID-19 patients. Screening - first day of treatment: After signing the i...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Study participants that have given informed consent before any study related procedures are performed, and received a copy of signed consent form
- Healthcare workers (nurses, doctors) employed and working at Gesundheitsverbund
- Healthcare workers looking after confirmed COVID-19 positive patients in a secondary care setting such as Accident and Emergency departments, wards, operating theatres, outpatient departments, High Dependency Unit or Intensive Care Units
Exclusion
- The subject is related to any study personnel or has any other close ties or conflicts of interest with the study sponsor.
- The subject has received any investigational drug or participated in a clinical trial within 4 weeks of entry to this study
- Known hypersensitivity or allergy to any component of the test product
- Severe cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease or a history or any current disease that is considered by the investigator as a reason for exclusion.
- The subject has a clinically significant disease that could interfere with participation in the study, with the intervention being studied, or with the evaluation of symptoms. Specific exclusions include immune deficiency, autoimmune disease, substantive cardiovascular, endocrinological, neurological, respiratory, or gastrointestinal disease.
- Asymptomatic disease such as elevated blood pressure or cholesterol will not be a reason for exclusion. Those with well-controlled mental illness (e.g. depression, anxiety) will be eligible. The enrolling physician will be empowered to exclude potential subjects that s/he deems unreliable.
- Pregnant women at the time of recruitment will be excluded from the study
- Current medication other than oral contraception, that is considered by the investigator as a reason for exclusion e.g. intranasal medication
- Participation in another antiviral clinical trial
Key Trial Info
Start Date :
December 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04681001
Start Date
December 20 2020
End Date
August 30 2021
Last Update
August 25 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Gesundheitsverbund, Klinik Favoriten
Vienna, Austria, 1100
2
Gesundheitsverbund Klinik Floridsdorf
Vienna, Austria, 1210